Diabetes Insipidus

Categories: Endocrine diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Diabetes Insipidus

MalaCards integrated aliases for Diabetes Insipidus:

Name: Diabetes Insipidus 12 73 29 6 42 44 15 70 32


External Ids:

Disease Ontology 12 DOID:9409
ICD9CM 34 253.5
MeSH 44 D003919
NCIt 50 C43263
SNOMED-CT 67 190484000
ICD10 32 E23.2
UMLS 70 C0011848

Summaries for Diabetes Insipidus

MedlinePlus : 42 Diabetes insipidus (DI) causes frequent urination. You become extremely thirsty, so you drink. Then you urinate. This cycle can keep you from sleeping or even make you wet the bed. Your body produces lots of urine that is almost all water. DI is different from diabetes mellitus (DM), which involves insulin problems and high blood sugar. The symptoms can be similar. However, DI is related to how your kidneys handle fluids. It's much less common than DM. Urine and blood tests can show which one you have. Usually, DI is caused by a problem with your pituitary gland or your kidneys. Treatment depends on the cause of the problem. Medicines can often help. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diabetes Insipidus is related to wolfram syndrome and hereditary nephrogenic diabetes insipidus. An important gene associated with Diabetes Insipidus is AVP (Arginine Vasopressin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Glucose / Energy Metabolism. The drugs Midazolam and Tolvaptan have been mentioned in the context of this disorder. Affiliated tissues include pituitary, hypothalamus and myeloid, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 73 Diabetes insipidus (DI) is a condition characterized by large amounts of dilute urine and increased... more...

Related Diseases for Diabetes Insipidus

Diseases in the Diabetes Insipidus family:

Hereditary Central Diabetes Insipidus Acquired Central Diabetes Insipidus

Diseases related to Diabetes Insipidus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 949)
# Related Disease Score Top Affiliating Genes
1 wolfram syndrome 32.7 WFS1 INS CRH CISD2 AVP
2 hereditary nephrogenic diabetes insipidus 32.6 AVPR2 AQP2
3 diabetes insipidus, neurohypophyseal 32.5 WFS1 PRL POMC OXT NPTX2 AVPR2
4 wolfram syndrome 1 32.4 WFS1 INS CRH CISD2 AVP
5 diabetes insipidus, nephrogenic, autosomal 32.3 SLC12A1 REN OXT CLCNKA AVPR2 AVPR1B
6 hydronephrosis 31.3 WFS1 SLC12A1 REN AQP2
7 pituitary hormone deficiency, combined, 2 31.2 PRL POMC AVP
8 hypopituitarism 31.1 PRL POMC INS CRH
9 secondary adrenal insufficiency 30.8 INS AVP
10 septooptic dysplasia 30.8 PRL POMC AVP
11 empty sella syndrome 30.7 PRL POMC INS
12 adenohypophysitis 30.7 PRL POMC
13 adenoma 30.7 REN PRL POMC CRH
14 nephrogenic syndrome of inappropriate antidiuresis 30.7 AVPR2 AVP AQP2
15 hyperprolactinemia 30.7 PRL POMC INS
16 pituitary gland disease 30.7 PRL POMC INS CRH AVP
17 pituitary apoplexy 30.6 PRL POMC INS AVP
18 hypoglycemia 30.5 PRL POMC INS CRH
19 bartter disease 30.5 SLC12A1 REN CLCNKA AVPR2 AVP AQP2
20 amenorrhea 30.5 PRL POMC INS CRH
21 familial glucocorticoid deficiency 30.5 REN POMC CRH
22 neurotic disorder 30.4 POMC OXT INS
23 hypokalemia 30.4 SLC12A1 REN POMC INS CRH AVPR2
24 oligohydramnios 30.3 REN OXT AFP
25 chromophobe adenoma 30.3 PRL POMC AVP
26 pain agnosia 30.3 POMC OXT CRH
27 acromegaly 30.3 PRL POMC INS CRH
28 diabetes mellitus 30.3 WFS1 REN PRL POMC INS CRH
29 polyhydramnios 30.3 SLC12A1 OXT AFP
30 central pontine myelinolysis 30.3 AVPR2 AVP AQP2
31 bartter syndrome, type 1, antenatal 30.2 SLC12A1 AQP2
32 hyperthyroidism 30.2 PRL POMC INS
33 pre-eclampsia 30.2 REN OXT INS CRH AFP
34 cranial nerve palsy 30.2 PRL POMC AVP
35 acute adrenal insufficiency 30.2 REN POMC
36 polycystic kidney disease 30.2 REN INS AVPR2 AVP AQP2
37 hypoaldosteronism 30.1 REN POMC
38 gitelman syndrome 30.1 SLC12A1 REN CLCNKA
39 idiopathic edema 30.1 INS AQP2
40 impotence 30.1 PRL POMC INS
41 inappropriate adh syndrome 30.1 REN POMC OXT CRH AVPR2 AVP
42 sheehan syndrome 30.1 PRL POMC INS CRH AVP
43 primary hyperparathyroidism 30.0 PRL POMC INS
44 abducens nerve disease 30.0 PRL POMC
45 pheochromocytoma 29.9 REN PRL POMC OXT CRH
46 functioning pituitary adenoma 29.9 PRL POMC CRH
47 dysthymic disorder 29.8 POMC INS CRH
48 ileus 29.8 POMC INS CRH
49 anovulation 29.8 PRL INS CRH
50 autosomal dominant polycystic kidney disease 29.7 REN INS AVPR2 AVP AQP2

Comorbidity relations with Diabetes Insipidus via Phenotypic Disease Network (PDN):

Acute Cystitis Diabetes Insipidus, Nephrogenic, Autosomal
Hypothyroidism Pituitary Hormone Deficiency, Combined, 2

Graphical network of the top 20 diseases related to Diabetes Insipidus:

Diseases related to Diabetes Insipidus

Symptoms & Phenotypes for Diabetes Insipidus

MGI Mouse Phenotypes related to Diabetes Insipidus:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.3 AFP AQP2 AVP AVPR1A AVPR1B AVPR2
2 homeostasis/metabolism MP:0005376 10.19 AFP AQP2 AVP AVPR1A AVPR1B AVPR2
3 endocrine/exocrine gland MP:0005379 10.06 AFP AVPR1A AVPR1B CISD2 CLCNKA CRH
4 integument MP:0010771 9.9 AQP2 AVPR2 CISD2 CLCNKA CRH INS
5 nervous system MP:0003631 9.73 ARHGAP4 AVP AVPR1A AVPR1B CISD2 CRH
6 renal/urinary system MP:0005367 9.36 AQP2 AVP AVPR2 CISD2 CLCNKA CRH

Drugs & Therapeutics for Diabetes Insipidus

Drugs for Diabetes Insipidus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
Tolvaptan Approved Phase 4 150683-30-0 216237
3 Coagulants Phase 4
4 Deamino Arginine Vasopressin Phase 4
5 Hemostatics Phase 4
6 Neurotransmitter Agents Phase 4
7 Psychotropic Drugs Phase 4
8 Pharmaceutical Solutions Phase 4
9 Anesthetics Phase 4
10 Vasoconstrictor Agents Phase 4
11 Hypnotics and Sedatives Phase 4
12 GABA Modulators Phase 4
13 Anesthetics, Intravenous Phase 4
14 Anesthetics, General Phase 4
15 Anti-Anxiety Agents Phase 4
16 diuretics Phase 4
Satavaptan Investigational Phase 3 185913-78-4 7029
Lithium carbonate Approved Phase 2 554-13-2
Atorvastatin Approved Phase 2 134523-00-5 60823
Dulaglutide Approved, Investigational Phase 2 923950-08-7
tannic acid Approved Phase 2 1401-55-4
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
23 Vasopressins Phase 2
24 Arginine Vasopressin Phase 2
25 Hypoglycemic Agents Phase 2
26 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
27 Antimetabolites Phase 2
28 Lipid Regulating Agents Phase 2
29 Anticholesteremic Agents Phase 2
30 Hypolipidemic Agents Phase 2
31 Hormones Phase 1, Phase 2
32 Glucagon-Like Peptide 1 Phase 2
Arginine Investigational, Nutraceutical Phase 2 74-79-3 6322
Metformin Approved Phase 1 657-24-9 4091 14219
Chlorothiazide Approved, Vet_approved 58-94-6 2720
Chlorpropamide Approved, Investigational 94-20-2 2727
Sodium citrate Approved, Investigational 68-04-2
Amiloride Approved 2016-88-8, 2609-46-3 16231
Salmon calcitonin Approved, Investigational 47931-85-1 16129616
Indomethacin Approved, Investigational 53-86-1 3715
Hydrochlorothiazide Approved, Vet_approved 58-93-5 3639
Lovastatin Approved, Investigational 75330-75-5 53232
Ethanol Approved 64-17-5 702
Polyestradiol phosphate Approved 28014-46-2
Progesterone Approved, Vet_approved 57-83-0 5994
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757
Ganirelix Approved 124904-93-4, 123246-29-7 25081094
Norepinephrine Approved 51-41-2 439260
Mannitol Approved, Investigational 69-65-8 6251 453
Glucagon Approved 16941-32-5

Interventional clinical trials:

(show top 50) (show all 75)
# Name Status NCT ID Phase Drugs
1 Pilot Study of the Relationship of Ambient Copeptin to the Aquaretic Effects of Tolvaptan in Patients With Heart Failure Completed NCT01346072 Phase 4 tolvaptan
2 1-deamino 8-d-arginine Vasopressin in Percutaneous Ultrasound-guided Renal Biopsy: a Randomized Controlled Trial Completed NCT00748072 Phase 4 DDAVP;saline solution
3 The Effect of Midazolam Premedication on Copeptine Concentration in Blood Completed NCT03474939 Phase 4 Midazolam Oral Tablet
4 Tolvaptan Treatment to Reverse Worsening Outpatient Heart Failure: Possible Role of Copeptin In Identifying Responders (TROUPER) Enrolling by invitation NCT02476409 Phase 4 tolvaptan
5 Acute Heart Failure With High Copeptin Levels Treated With Tolvaptan Targets Increased AVP Activation for Treatment Efficacy Unknown status NCT01733134 Phase 3 Tolvaptan;placebo
6 Peroral Administration of Different Doses of Desmopressin Administered as a New Orally-Disintegrating Tablet and Desmopressin for Nasal Administration in the Treatment of CDI in Japanese Patients Completed NCT01280188 Phase 3 Desmopressin Oral Melt;Desmopressin intranasal
7 A Randomized, Double-Blind, Placebo-Group, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT00264927 Phase 3 SR121463B
8 An Open-Label, Multicenter Study Evaluating the Long-Term Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT00264914 Phase 3 SR121463B
9 A Multicenter, Uncontrolled, Open-label, Dose-titration Trial to Investigate the Efficacy and Safety of Tolvaptan Tablets in Patients With Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Completed NCT03048747 Phase 3 Tolvaptan Oral Tablet
10 Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus: A Randomized Controlled Trial Completed NCT02967653 Phase 2 Atorvastatin
11 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion. Completed NCT00032734 Phase 2 satavaptan (SR121463B)
12 Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia: "The GOLD-Study" Completed NCT02770885 Phase 2 Dulaglutide;Placebo
13 AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock Completed NCT01611935 Phase 2 Vasopressin
14 A Phase 1b, Multicenter, Pilot, Randomized, Double-blind Trial to Determine the Pharmacokinetics and Pharmacodynamics of Orally Administered Tolvaptan 3.75, 7.5, and 15 mg Tablets in Subjects With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT02009878 Phase 1, Phase 2 tolvaptan
15 The Influence of Vasopressin on Observational Learning of Placebo Analgesia Active, not recruiting NCT03446456 Phase 1, Phase 2 Arginine vasopressin
16 Effects of Intranasal Oxytocin in Patients With Central Diabetes Insipidus - A Pilot Study Not yet recruiting NCT04789148 Phase 1 Oxytocin nasal spray
17 Use of Metformin to Treat Patients With Congenital Nephrogenic Diabetes Insipidus (NDI) Terminated NCT02460354 Phase 1 Metformin
18 Study of Novel Types of Familial Diabetes Insipidus Unknown status NCT00004364 desmopressin
19 Study of Prognostic Value of Copeptin for Myocardial Infarct Size and 6-month Prognosis in Patients With ST-elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: GOOD I Study Unknown status NCT03074214
20 Evaluation of Copeptin in Patients With Cirrhosis and Ascites Unknown status NCT03318601
21 Diagnostic Utility of Copeptin in Addition to High-sensitivity Cardiac Troponin for the Early Diagnosis of Non-ST-Elevation Acute Coronary Syndromes - The COPACS Study Unknown status NCT01962506
22 Copeptin as a Novel Diagnostic and Prognostic Marker in the Management of Neurological and Neurosurgical Patients With Sodium Imbalance The "COSMOS"-Study (Copeptin in Osmoregulation and Stress Assessment) Completed NCT00390962
23 Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus Completed NCT00004360 chlorothiazide
24 Copeptin in Differentiation of Polyuria and Polydipsia Completed NCT01056887
25 Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed NCT00004363 chlorpropamide;desmopressin
26 Use of Copeptin in the Differential Diagnosis of Diabetes insipidus-a Prospective International Study Completed NCT01940614
27 Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus Completed NCT00478335 sildenafil;calcitonin;hydrochlorothiazide/amiloride;indomethacin;Placebo for sildenafil;placebo for calcitonin
28 Copeptin in the Diagnosis and Differential Diagnosis of Diabetes Insipidus. The CoSIP-Study Completed NCT00757276
29 Peer Support to Enhance Diabetes Shared Medical Appointments: Examining Comparative Effectiveness in VA Health Systems Completed NCT02132676
30 Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis Completed NCT01465672
31 Copeptin During a Standardized Oral Glucose Tolerance Test and a Mixed Meal Tolerance Test Completed NCT01772914
32 Copeptin Serum Level in Liver Transplant Recipients Completed NCT03587623
33 Evaluation of Copeptin Levels in Elective Cesarean Section With Spinal and General Anesthesia and Their Relationship With Fetal Stress: Prospective Study Completed NCT03536910
34 Value of Copeptin and the S-100b Protein Assay in Ruling Out the Diagnosis of Stroke-induced Dizziness Pattern in Emergency Departments Completed NCT03974464
35 Urinary AQP2 Excretion in Hypercholesterolemic Patients as a Measure of Effect of Statin Therapy Completed NCT02523001
36 Copeptin for Risk Stratification in Non-traumatic Headache in the Emergency Setting - The CoHead Study Completed NCT01174901
37 Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19 Completed NCT02490969
38 Copeptin After Arginine Infusion for the Differential Diagnosis of the Polyuria-Polydipsia Syndrome ''The CARGO-Study'' Completed NCT01879137
39 Study of Prognosis Value of Protein S100Beta and Copeptine in Seizure in the Emergency Department Completed NCT01774500
40 Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers - The Macicop-Study Completed NCT03844217 Macimorelin 0.5mg/kg body weight;Macimorelin 0.75mg/kg body weight
41 Evaluation of Serum Copeptin and Psychological Stress Level Among Healthcare Providers During COVID-19 Pandemic Completed NCT04757285
42 Copeptin During a Standardized Psychological Stress Test Completed NCT01866137
43 Serum Copeptin as a Predictor of the Risk of Hyponatremia After Transurethral Prostatectomy Completed NCT03912766
44 Proadrenomedullin and Copeptin as Predictors of Vasopressor Requirements and Volume Resuscitation in Patients With Septic Shock Completed NCT03104933
45 The Effect of Integrating the Biomarker Copeptin Into the Process of Managing Patients With Suspected ACS Completed NCT01498731
46 Vasopressin Deficiency in Hemorrhagic Shock Completed NCT01107314
47 The Influence of Water and Salt Intake on Copeptin Levels During Moderate Alcohol Consumption - a Pathophysiological Study Completed NCT03883503
48 The Effects of Estradiol and Progesterone on Arginine Vasopressin Regulation and Serum Sodium Concentration Completed NCT00589134
49 Diagnostic Value of Copeptin Assay for Acute Coronary Syndrome Without ST-segment Elevation Completed NCT01334645
50 Serial Vasopressin and Copeptin Levels in Children With Sepsis and Septic Shock Completed NCT00698048

Search NIH Clinical Center for Diabetes Insipidus

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Desmopressin Acetate
Vasopressin (USP)

Cochrane evidence based reviews: diabetes insipidus

Genetic Tests for Diabetes Insipidus

Genetic tests related to Diabetes Insipidus:

# Genetic test Affiliating Genes
1 Diabetes Insipidus 29

Anatomical Context for Diabetes Insipidus

MalaCards organs/tissues related to Diabetes Insipidus:

Pituitary, Hypothalamus, Myeloid, Pineal, Thyroid, Cortex, Adrenal Cortex

Publications for Diabetes Insipidus

Articles related to Diabetes Insipidus:

(show top 50) (show all 8782)
# Title Authors PMID Year
Simplified and improved fluid deprivation test for diagnosing diabetes insipidus. 61 42
33112270 2021
Excess Mortality Among Hospitalized Patients With Hypopituitarism-A Population-Based, Matched-Cohort Study. 42 61
32785679 2020
Diabetes Insipidus After Endoscopic Transsphenoidal Surgery. 61 42
32503055 2020
In Vitro and In Vivo Evidence on the Role of Mitochondrial Impairment as a Mechanism of Lithium-Induced Nephrotoxicity. 61
32712907 2021
A patient with congenital nephrogenic diabetes insipidus due to AVPR2 mutation complicated by persisting polydipsia under hemodialysis treatment. 61
33125666 2021
Lithium toxicity and the kidney with special focus on nephrotic syndrome associated with the acute kidney injury: A case-based systematic analysis. 61
33798272 2021
Mild Phenotype of Wolfram Syndrome Associated With a Common Pathogenic Variant Is Predicted by a Structural Model of Wolframin. 61
33763535 2021
Transsphenoidal Resection of Pituitary Tumors in the United States, 2009 to 2011: Effects of Hospital Volume on Postoperative Complications. 61
33777631 2021
Diabetes insipidus and acute myeloid leukemia harboring monosomy 7: report of two cases and literature review. 61
31452466 2021
Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces. 61
33393372 2021
Gefitinib Treatment Was Unsuccessful for Central Diabetes Insipidus Due to Pituitary Metastasis of Lung Adenocarcinoma. 61
33162476 2021
Unusual case presentation of fungal ball infection causing diabetes insipidus and seizure disorder. 61
33537110 2021
Surgery versus conservative care for Rathke's cleft cyst. 61
33450264 2021
Sevoflurane sedation and nephrogenic diabetes insipidus in patients affected with severe acute respiratory syndrome coronavirus 2. 61
33661827 2021
Unusual ischemic kidney injury presenting as slowly declining graft function and successful use of oral desmopressin in a kidney transplant recipient with subclinical central diabetes insipidus. 61
33560220 2021
Vasopressin-Dependent Disorders: What Is New in Children? 61
33795481 2021
Postoperative diabetes insipidus: how to define and grade this complication? 61
32990908 2021
Delayed Onset of Central Diabetes Insipidus With Ketamine Sedation: A Report of 2 Cases. 61
31648586 2021
Diagnosis and management of diabetes insipidus for the internist: an update. 61
33713498 2021
Growth hormone deficiency and other endocrinopathies after childhood brain tumors: results from a close follow-up in a cohort of 242 patients. 61
33683662 2021
Endoscopic Endonasal Approach to Multilobular Giant Pituitary Adenoma with Cavernous Sinus Invasion and Petroclival Extension. 61
33220473 2021
Langerhans Cell Histiocytosis of the Orbit: Spectrum of Clinical and Imaging Findings. 61
33157073 2021
Endoscopic extended transsphenoidal surgery for newly diagnosed paediatric craniopharyngiomas. 61
33665678 2021
Deficiency of WFS1 leads to the impairment of AVP secretion under dehydration in male mice. 61
33666833 2021
Collaboration for rare diabetes: understanding new treatment options for Wolfram syndrome. 61
33527330 2021
Novel mutations in the WFS1 gene are associated with Wolfram syndrome and systemic inflammation. 61
33693650 2021
A case series and review of the mononostril endoscopic transnasal transsphenoidal approach: Safe and effective in a low resource setting. 61
33493882 2021
Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia. 61
33369023 2021
First voided volume: A novel approach to characterize nocturia. 61
33604915 2021
Histopathological findings in the landscape of IgG4-related pathology in patients with pituitary dysfunction: Review of six cases. 61
33615590 2021
Pregnancy-associated diabetes insipidus in Japan-a review based on quoting from the literatures reported during the period from 1982 to 2019. 61
33775975 2021
Multifactorial diabetes insipidus during pregnancy: a challenging diagnosis. 61
33722910 2021
An AMPK activator as a therapeutic option for congenital nephrogenic diabetes insipidus. 61
33724959 2021
Valine-279 Deletion-Mutation on Arginine Vasopressin Receptor 2 Causes Obstruction in G-Protein Binding Site: A Clinical Nephrogenic Diabetes Insipidus Case and Its Sub-Molecular Pathogenic Analysis. 61
33804115 2021
Dysregulation of Principal Cell miRNAs Facilitates Epigenetic Regulation of AQP2 and Results in Nephrogenic Diabetes Insipidus. 61
33727367 2021
Clinical Characteristics of Primary Hypophysitis - A Single-Centre Series of 60 Cases. 61
32770534 2021
Pituitary surgery in elderly patients: a safe and effective procedure. 61
33665774 2021
Outcomes of endoscopic transsphenoidal surgery for Cushing's disease. 61
33658018 2021
A novel mutation of PCSK1 responsible for PC1/3 deficiency in two siblings. 61
33662777 2021
Diabetes insipidus secondary to sellar/parasellar lesions. 61
33769630 2021
Renal Disease in Primary Sjögren's Syndrome. 61
33367966 2021
Diabetes insipidus with impaired vision caused by germinoma and perioptic meningeal seeding: A case report. 61
33748249 2021
Impact of sleep, neuroendocrine, and executive function on health-related quality of life in young people with craniopharyngioma. 61
33754350 2021
Rapid Development of Vasopressin Resistance in Dietary Potassium Deficiency. 61
33749322 2021
Exogenous central angiotensin fails to stimulate a sodium appetite in diabetes insipidus Brattleboro rats. 61
33387586 2021
Diabetes Insipidus: To Treat or Not to Treat? 61
33516432 2021
Incidence of hyperkalemia during hypertonic saline test for the diagnosis of diabetes insipidus. 61
33666570 2021
Early pulse glucocorticoid therapy and improved hormonal outcomes in primary hypophysitis. 61
33744880 2021
Neuroendocrine Dysfunction in the Acute Setting of Penetrating Brain Injury: A Systematic Review. 61
33346052 2021
Resection of an Isolated Pituitary Stalk Epidermoid Cyst Through a Pretemporal Approach: Case Report and Review of the Literature. 61
32920157 2021

Variations for Diabetes Insipidus

ClinVar genetic disease variations for Diabetes Insipidus:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MATN4 NM_003833.4(MATN4):c.515G>C (p.Gly172Ala) SNV Likely pathogenic 183295 rs730882210 GRCh37: 20:43932996-43932996
GRCh38: 20:45304356-45304356

Expression for Diabetes Insipidus

Search GEO for disease gene expression data for Diabetes Insipidus.

Pathways for Diabetes Insipidus

GO Terms for Diabetes Insipidus

Cellular components related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 REN PRL POMC OXT INS CRH
2 secretory granule GO:0030141 9.33 POMC OXT AVP
3 extracellular region GO:0005576 9.32 REN PRL POMC OXT NPTX2 MATN4
4 endosome lumen GO:0031904 9.26 PRL INS

Biological processes related to Diabetes Insipidus according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.16 PRL POMC OXT INS CRH AVPR2
2 G protein-coupled receptor signaling pathway GO:0007186 10.08 POMC OXT INS CRH AVPR2 AVPR1B
3 positive regulation of cell proliferation GO:0008284 10 PRL INS CRH AVPR2 AVPR1A AVP
4 cellular protein metabolic process GO:0044267 9.93 WFS1 PRL INS AFP
5 positive regulation of cytosolic calcium ion concentration GO:0007204 9.87 OXT AVPR1B AVPR1A AVP
6 glucose homeostasis GO:0042593 9.83 WFS1 POMC INS
7 female pregnancy GO:0007565 9.82 PRL OXT CRH
8 positive regulation of cell growth GO:0030307 9.81 INS AVPR1A AVP
9 social behavior GO:0035176 9.78 OXT AVPR1A AVP
10 generation of precursor metabolites and energy GO:0006091 9.75 POMC AVPR1A AVP
11 water transport GO:0006833 9.65 AVP AQP2
12 positive regulation of renal sodium excretion GO:0035815 9.65 OXT AVPR1A
13 drinking behavior GO:0042756 9.63 REN OXT
14 positive regulation of prostaglandin biosynthetic process GO:0031394 9.62 AVPR1A AVP
15 positive regulation of glutamate secretion GO:0014049 9.62 AVPR1A AVP
16 hyperosmotic salinity response GO:0042538 9.61 OXT AVP
17 positive regulation of blood pressure GO:0045777 9.61 OXT AVPR2 AVPR1A
18 negative regulation of transmission of nerve impulse GO:0051970 9.6 AVPR1A AVP
19 sperm ejaculation GO:0042713 9.59 OXT AVPR1A
20 negative regulation of urine volume GO:0035811 9.58 OXT AVPR2
21 grooming behavior GO:0007625 9.58 OXT AVPR1A AVP
22 response to ether GO:0045472 9.56 OXT CRH
23 renal water homeostasis GO:0003091 9.56 WFS1 AVPR2 AVP AQP2
24 positive regulation of cellular pH reduction GO:0032849 9.55 AVPR1A AVP
25 negative regulation of female receptivity GO:0007621 9.54 AVPR1A AVP
26 positive regulation of systemic arterial blood pressure GO:0003084 9.54 AVPR2 AVPR1A AVP
27 penile erection GO:0043084 9.51 AVPR1A AVP
28 maternal behavior GO:0042711 9.5 OXT AVPR1A AVP
29 cellular response to water deprivation GO:0042631 9.49 AVPR1A AQP2
30 positive regulation of vasoconstriction GO:0045907 9.46 AVPR2 AVPR1B AVPR1A AVP
31 regulation of systemic arterial blood pressure by vasopressin GO:0001992 9.13 AVPR2 AVPR1B AVPR1A
32 maternal aggressive behavior GO:0002125 8.8 OXT AVPR1A AVP

Molecular functions related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide binding GO:0042277 9.54 AVPR2 AVPR1B AVPR1A
2 neuropeptide hormone activity GO:0005184 9.5 OXT CRH AVP
3 insulin-like growth factor receptor binding GO:0005159 9.4 REN INS
4 V1A vasopressin receptor binding GO:0031894 9.26 AVPR1A AVP
5 neurohypophyseal hormone activity GO:0005185 9.16 OXT AVP
6 vasopressin receptor activity GO:0005000 9.13 AVPR2 AVPR1B AVPR1A
7 hormone activity GO:0005179 9.1 PRL POMC OXT INS CRH AVP

Sources for Diabetes Insipidus

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....